Content continues after advertisement

Neurologic Signs in a Dog with Demodicosis

Sandra Nogueira Koch, DVM, MS, Diplomate ACVD, University of Minnesota

Toxicology

|
June 2011
|
Peer Reviewed

Sign in to Print/View PDF

Neurologic Signs in a Dog with Demodicosis

A 2-year-old castrated male boxer was presented for tremors and incoordination.

History
Tremors and incoordination occurred about 5 hours after the dog received a single dose (30 mg/kg PO) of the flea preventive spinosad (Comfortis, elanco.com).

The dog had been diagnosed with young-onset generalized demodicosis and secondary superficial pyoderma 3 months earlier. At that time, treatment was initiated with ivermectin 1% (0.6 mg/kg PO Q 24 H), cephalexin (30 mg/kg PO Q 12 H), and benzoyl peroxide shampoo (Pyoben, virbacvet.com) twice weekly. He responded well to treatment, and because the superficial pyoderma resolved 2 months after cephalexin treatment was initiated, that drug was discontinued.

Physical Examination
The dog was lethargic and ataxic and had bilateral mydriasis. There was mild generalized alopecia but evidence of hair regrowth. No other physical abnormalities were noted.

Laboratory Results
Complete blood count and serum biochemical profile results were unremarkable. Skin scrapings revealed a few Demodex mites.

Ask Yourself...
1. What is the most likely cause of this dog’s neurologic signs?
A. Ivermectin toxicity
B. Spinosad toxicity
C. Drug interaction toxicity (ivermectin & spinosad)
D. Unrelated to prescribed medications

2. How would you manage the neurologic signs?
A. Provide supportive care
B. Discontinue ivermectin
C. Discontinue spinosad
D. A, B, and C

CORRECT ANSWERS:
1C. Drug interaction toxicity (ivermectin & spinosad)
2D. A, B, & C

Ivermectin and spinosad were discontinued, and the owner was instructed to provide supportive care until clinical signs resolved.

Ivermectin
Ivermectin is not approved by the U.S. Food and Drug Administration (FDA) for treatment of canine demodicosis; however, daily oral administration of extralabel high doses (0.4–0.6 mg/kg Q 24 H) of the drug is commonly used for this purpose. The most common causes of ivermectin toxicity are related to administration of high doses (10–20 times the recommended dose) and breed sensitivity. Signs of ivermectin toxicity include lethargy, tremors, vomiting, drooling, ataxia, mydriasis, stupor, and coma; this toxicity may result in death.

Signs of Ivermectin Toxicity

  • Ataxia
  • Drooling
  • Lethargy
  • Mydriasis
  • Tremors
  • Vomiting
  • Coma
  • Death
  • Stupor

Spinosad
Spinosad is used orally on a monthly basis for prevention and treatment of flea infestations. The most common side effect associated with spinosad is vomiting, but lethargy, diarrhea, cough, increased thirst, vocalization, increased or decreased appetite, erythema, hyperactivity, and excessive salivation may also be noted. No neurologic signs have been reported in open-label dose response clinical trials for spinosad.

Drug Interaction
The neurologic signs presented in this case are consistent with ivermectin toxicity; however, neurotoxic effects of ivermectin used alone usually occur during the first few days or weeks of therapy. In addition, the neurologic signs occurred shortly after spinosad administration in this case. Therefore, the lack of neurologic signs during the first 3 months of ivermectin therapy and the sudden onset of neurologic signs after spinosad administration suggest that in this dog the signs were likely due to a drug interaction.

Treatment
Discontinuation of ivermectin and spinosad therapy, along with symptomatic and supportive care, is important for recovery. An antidote for ivermectin toxicity (physostigmine) may be used if needed. Once the dog recovers, demodicosis drug treatment and flea preventive should be carefully reinitiated avoiding the use of the 2 drugs concurrently or using alternative medications.

FDA & Manufacturer Recommendations
On June 24, 2008, the FDA Center for Veterinary Medicine and Elanco Companion Animal Health reported adverse reactions consistent with ivermectin toxicity in dogs receiving ivermectin and spinosad concurrently. Veterinarians were advised that dogs receiving extralabel high doses of ivermectin should not receive concurrent treatment with spinosad.

According to the manufacturer, concurrent administration of spinosad and approved canine ivermectin and milbemycin oxime at doses labeled for heartworm prevention has been tested and shown to be safe, even when used in dogs carrying the ABCB1 (previously MDR1) gene mutation that causes avermectin sensitivity.

Potential Pathophysiology
To date, concurrent administration of extralabel doses of ivermectin and spinosad has not been evaluated in laboratory or field studies. Ivermectin is an agonist for the neurotransmitter gammaaminobutyric acid (GABA). Although spinosad has a novel mode of action, primarily targeting nicotinic acetylcholine receptors, it also has secondary effects on GABA neurotransmission. The effect of both drugs on GABA has been speculated as a possible cause of the observed ivermectin neurotoxicity; however, inhibition of P-glycoprotein, which would increase ivermectin access to the central nervous system, has also been proposed as a potential explanation for the response.1

Take-Home Messages

  • Ivermectin for the treatment of canine demodicosis is extralabel and requires careful vigilance for unexpected reactions, mainly with concurrent administration of other drugs.
  • Use of spinosad in dogs receiving extralabel high doses of ivermectin should be avoided.
  • Spinosad is approved and safe for use with labeled doses of heartworm preventives.
  • Discontinuation of ivermectin and spinosad, along with supportive
    therapy, should lead to complete cessation of neurotoxic effects.

References

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | Privacy Policy | Acceptable Use Policy